1. Home
  2. RCG vs CUE Comparison

RCG vs CUE Comparison

Compare RCG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RCG

RENN Fund Inc

HOLD

Current Price

$2.65

Market Cap

18.1M

Sector

Finance

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$20.49

Market Cap

17.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCG
CUE
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
17.6M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
RCG
CUE
Price
$2.65
$20.49
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
4.9K
845.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.11
EPS
N/A
N/A
Revenue
N/A
$27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
195.75
52 Week Low
$2.40
$0.17
52 Week High
$3.31
$41.42

Technical Indicators

Market Signals
Indicator
RCG
CUE
Relative Strength Index (RSI) 42.44 51.08
Support Level $2.48 $0.30
Resistance Level $2.80 $41.42
Average True Range (ATR) 0.07 3.34
MACD 0.01 -1.83
Stochastic Oscillator 51.96 10.28

Price Performance

Historical Comparison
RCG
CUE

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: